Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T12:50:53.201Z.
Calculation as of: 2026-10-06T12:50:53.201Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 396f74b358d2be52688229160785b883c1ccba5e7e57b4b59ce0869c705c56f9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$416.68M
Free Cash Flow Yield
N/A
TTM Avg
13.37%
3Y Avg
10.70%
5Y Avg
10.70%
Market Cap
$410.54M
Free Cash Flow Yield
N/A
TTM Avg
24.51%
3Y Avg
24.51%
5Y Avg
24.51%
Market Cap
$408.21M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$406.47M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$428.16M
Free Cash Flow Yield
N/A
TTM Avg
2.75%
3Y Avg
2.75%
5Y Avg
2.75%
Market Cap
$447.43M
Free Cash Flow Yield
N/A
TTM Avg
4.98%
3Y Avg
4.98%
5Y Avg
4.98%
Market Cap
$450.64M
Free Cash Flow Yield
N/A
TTM Avg
28.70%
3Y Avg
28.70%
5Y Avg
28.70%
Market Cap
$453.70M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $415.93M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | N/A | 13.37% | 10.70% | 10.70% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | N/A | 24.51% | 24.51% | 24.51% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | N/A | 2.75% | 2.75% | 2.75% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | N/A | 4.98% | 4.98% | 4.98% |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | N/A | 28.70% | 28.70% | 28.70% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $373.40M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
